Psilocybin-occasioned mystical-type experience in comspiritual practices produces enduring positive changes in trait measures of prosocial attitudes and behaviors

Journal of Psychopharmacology 32, 49-69

DOI: 10.1177/0269881117731279

Citation Report

#	Article	IF	CITATIONS
1	Long-lasting subjective effects of LSD in normal subjects. Psychopharmacology, 2018, 235, 535-545.	1.5	137
2	Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study. Frontiers in Psychology, 2018, 9, 2459.	1.1	54
3	Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. International Review of Psychiatry, 2018, 30, 291-316.	1.4	115
4	"To learn healing knowledge― Philosophy, psychedelic studies and transformation. South African Journal of Philosophy, 2018, 37, 438-451.	0.3	2
5	Psychedelics and the new behaviourism: considering the integration of third-wave behaviour therapies with psychedelic-assisted therapy. International Review of Psychiatry, 2018, 30, 343-349.	1.4	45
6	Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy. International Review of Psychiatry, 2018, 30, 331-342.	1.4	98
7	The Science and Theology of Dreams. Theology and Science, 2018, 16, 484-497.	0.2	0
8	Does human language limit translatability of clinical and preclinical addiction research?. Neuropsychopharmacology, 2018, 43, 1985-1988.	2.8	17
9	High dose psilocybin is associated with positive subjective effects in healthy volunteers. Journal of Psychopharmacology, 2018, 32, 770-778.	2.0	46
10	Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition. Psychopharmacology, 2018, 235, 2915-2927.	1.5	58
11	Psilocybin and Mental Health–Don't Lose Control. Frontiers in Psychiatry, 2018, 9, 293.	1.3	13
12	Psychedelics, Meditation, and Self-Consciousness. Frontiers in Psychology, 2018, 9, 1475.	1.1	179
13	The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology, 2018, 142, 143-166.	2.0	184
14	LIMITATIONS ON THE SCIENTIFIC STUDY OF DRUGâ€ENABLED MYSTICAL EXPERIENCES. Zygon, 2019, 54, 756-79	920.2	4
15	Death in Ancient Chinese Thought: What Confucians and Daoists Can Teach Us About Living and Dying Well. Comparative Philosophy of Religion, 2019, , 11-38.	0.1	1
16	Replication and extension of a model predicting response to psilocybin. Psychopharmacology, 2019, 236, 3221-3230.	1.5	49
17	Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. PLoS ONE, 2019, 14, e0214377.	1.1	132
18	Beyond LSD: A Broader Psychedelic Zeitgeist during the Early to Mid-20 <sup>th</sup> Century. Journal of Psychoactive Drugs, 2019, 51, 210-217.	1.0	9

#	ARTICLE	IF	Citations
19	Psychedelic-Assisted Group Therapy: A Systematic Review. Journal of Psychoactive Drugs, 2019, 51, 174-188.	1.0	54
20	Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects. NeuroImage, 2019, 196, 207-215.	2.1	144
21	A systematic study of microdosing psychedelics. PLoS ONE, 2019, 14, e0211023.	1.1	143
22	Modulation of Social Cognition via Hallucinogens and "Entactogens― Frontiers in Psychiatry, 2019, 10, 881.	1.3	29
23	Psychedelics and potential benefits in "healthy normals― A review of the literature. Journal of Psychedelic Studies, 2019, 3, 280-287.	0.5	15
24	From Egoism to Ecoism: Psychedelics Increase Nature Relatedness in a State-Mediated and Context-Dependent Manner. International Journal of Environmental Research and Public Health, 2019, 16, 5147.	1.2	75
25	Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat. Scientific Reports, 2019, 9, 14914.	1.6	79
26	Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function., 2019, 197, 83-102.		296
27	Awakening and Recovery. Alcoholism Treatment Quarterly, 2020, 38, 266-285.	0.5	5
28	Exploring the case for research on incorporating psychedelics within interventions for borderline personality disorder. Journal of Contextual Behavioral Science, 2020, 15, 1-11.	1.3	47
29	Embedding existential psychology within psychedelic science: reduced death anxiety as a mediator of the therapeutic effects of psychedelics. Psychopharmacology, 2020, 237, 21-32.	1.5	27
30	Studying the Effects of Meditation. , 0, , .		3
31	Advancing elite athlete mental health treatment with psychedelic-assisted psychotherapy. Journal of Applied Sport Psychology, 2020, , $1-19$ .	1.4	1
32	Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nature Reviews Neuroscience, 2020, 21, 611-624.	4.9	244
33	Understanding the Nature of Oneness Experience in Meditators Using Collective Intelligence Methods. Frontiers in Psychology, 2020, 11, 2092.	1.1	7
34	The potential synergistic effects between psychedelic administration and nature contact for the improvement of mental health. Health Psychology Open, 2020, 7, 205510292097812.	0.7	32
35	Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis. Psychological Medicine, 2020, 50, 2655-2666.	2.7	33
36	Personality Traits in Former Spanish Substance Users Recovered with Ayahuasca. Journal of Psychoactive Drugs, 2020, 52, 264-272.	1.0	14

#	ARTICLE	IF	Citations
37	Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments. Expert Review of Clinical Pharmacology, 2020, 13, 655-670.	1.3	41
38	Compassionate use of psychedelics. Medicine, Health Care and Philosophy, 2020, 23, 485-496.	0.9	10
39	Psilocybin occasioned mysticalâ€ŧype experiences. Human Psychopharmacology, 2020, 35, e2742.	0.7	16
40	Mystical Experiences in Retrospective Reports of First Times Using a Psychedelic in Finland. Journal of Psychoactive Drugs, 2020, 52, 309-318.	1.0	18
41	Long-term effects of psychedelic drugs: A systematic review. Neuroscience and Biobehavioral Reviews, 2020, 113, 179-189.	2.9	96
42	Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects. Journal of Psychoactive Drugs, 2020, 52, 273-281.	1.0	20
43	A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding. European Neuropsychopharmacology, 2020, 33, 71-80.	0.3	88
44	Psychedelics and Psychedelic-Assisted Psychotherapy. American Journal of Psychiatry, 2020, 177, 391-410.	4.0	309
45	Emotions and brain function are altered up to one month after a single high dose of psilocybin. Scientific Reports, 2020, 10, 2214.	1.6	169
46	Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance. Frontiers in Psychiatry, 2020, 11, 5.	1.3	84
47	Transformative experience and social connectedness mediate the mood-enhancing effects of psychedelic use in naturalistic settings. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 2338-2346.	3.3	79
48	Inhaled 5-methoxy-N,N-dimethyltryptamine: Supportive context associated with positive acute and enduring effects. Journal of Psychedelic Studies, 2020, 4, 114-122.	0.5	14
49	Some Comments on Psychedelic Research. American Journal of Psychiatry, 2020, 177, 368-369.	4.0	10
50	The Viability of Microdosing Psychedelics as a Strategy to Enhance Cognition and Well-being - An Early Review. Journal of Psychoactive Drugs, 2020, 52, 300-308.	1.0	13
51	Serotonin and serotonin receptors in hallucinogen action. Handbook of Behavioral Neuroscience, 2020, 31, 843-863.	0.7	2
52	Depression, Mindfulness, and Psilocybin: Possible Complementary Effects of Mindfulness Meditation and Psilocybin in the Treatment of Depression. A Review. Frontiers in Psychiatry, 2020, 11, 224.	1.3	37
53	Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. JAMA Psychiatry, 2021, 78, 481.	6.0	648
54	Upward spirals of positive emotions and religious behaviors. Current Opinion in Psychology, 2021, 40, 92-98.	2.5	23

#	Article	IF	Citations
55	Acute subjective effects in LSD- and MDMA-assisted psychotherapy. Journal of Psychopharmacology, 2021, 35, 362-374.	2.0	38
56	Pivotal mental states. Journal of Psychopharmacology, 2021, 35, 319-352.	2.0	71
57	Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms. Pharmacological Reviews, 2021, 73, 202-277.	7.1	110
58	The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects. ACS Pharmacology and Translational Science, 2021, 4, 568-572.	2.5	223
59	Racial Justice Requires Ending the War on Drugs. American Journal of Bioethics, 2021, 21, 4-19.	0.5	67
60	Using Psychedelics With Therapeutic Intent Is Associated With Lower Shame and Complex Trauma Symptoms in Adults With Histories of Child Maltreatment. Chronic Stress, 2021, 5, 247054702110298.	1.7	19
61	Psychedelics and Psychedelic-Assisted Psychotherapy. Focus (American Psychiatric Publishing), 2021, 19, 95-115.	0.4	6
62	Entity encounters and the therapeutic effect of the psychedelic mystical experience. Journal of Evolutionary Psychology, 2021, 4, 171-178.	1.4	10
63	The acute effects of classic psychedelics on memory in humans. Psychopharmacology, 2021, 238, 639-653.	1.5	32
64	Tripping over the other: Could psychedelics increase empathy?. Journal of Evolutionary Psychology, 2021, 4, 163-170.	1.4	11
65	Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches. Journal of Psychopharmacology, 2021, 35, 353-361.	2.0	49
67	Dose–response relationships of psilocybin-induced subjective experiences in humans. Journal of Psychopharmacology, 2021, 35, 384-397.	2.0	38
68	Examining changes in personality following shamanic ceremonial use of ayahuasca. Scientific Reports, 2021, 11, 6653.	1.6	44
69	Associations between lifetime classic psychedelic use and markers of physical health. Journal of Psychopharmacology, 2021, 35, 447-452.	2.0	41
70	Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice. ACS Pharmacology and Translational Science, 2021, 4, 416-423.	2.5	31
71	Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects. ACS Pharmacology and Translational Science, 2021, 4, 424-435.	2.5	109
72	A quantitative exploration of the relationships between regular yoga practice, microdosing psychedelics, wellbeing and personality variables. Australian Journal of Psychology, 2021, 73, 134-143.	1.4	5
73	From †molecules of life' to new therapeutic approaches, an evolution marked by the advent of artificial intelligence: the cases of chronic pain and neuropathic disorders. Drug Discovery Today, 2021, 26, 1070-1075.	3.2	1

#	Article	IF	CITATIONS
74	Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?. Journal of Psychopharmacology, 2022, 36, 6-11.	2.0	28
75	Lifetime use of psychedelics is associated with better mental health indicators during the COVID-19 pandemic. Journal of Psychedelic Studies, 2021, 5, 83-93.	0.5	8
76	Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities. International Journal of Neuropsychopharmacology, 2021, 24, 615-623.	1.0	20
77	Four individuals' experiences during and following a psilocybin truffle retreat in the Netherlands. Journal of Psychedelic Studies, 2021, 5, 22-32.	0.5	6
78	Sustained, Multifaceted Improvements in Mental Well-Being Following Psychedelic Experiences in a Prospective Opportunity Sample. Frontiers in Psychiatry, 2021, 12, 647909.	1.3	21
79	Psychedelic drug use and schizotypy in young adults. Scientific Reports, 2021, 11, 15058.	1.6	8
80	Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy. American Journal of Psychotherapy, 2021, 74, 140-149.	0.4	46
81	Current Perspective on the Therapeutic Preset for Substance-Assisted Psychotherapy. Frontiers in Psychology, 2021, 12, 617224.	1.1	28
82	Spiritual Benefit from Cannabis. Journal of Psychoactive Drugs, 2022, 54, 149-157.	1.0	7
83	Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?. Frontiers in Psychiatry, 2021, 12, 661233.	1.3	41
84	Associations between ayahuasca consumption in naturalistic settings and current alcohol and drug use: Results of a large international crossâ€sectional survey. Drug and Alcohol Review, 2022, 41, 265-274.	1.1	24
85	LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model. Psychological Medicine, 2023, 53, 1151-1165.	2.7	20
86	Effects of Ayahuasca on Personality: Results of Two Randomized, Placebo-Controlled Trials in Healthy Volunteers. Frontiers in Psychiatry, 2021, 12, 688439.	1.3	10
87	Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy. Frontiers in Psychiatry, 2021, 12, 707057.	1.3	20
88	The Role of Psilocybin-Assisted Psychotherapy to Support Patients With Cancer: A Critical Scoping Review of the Research. Journal of Holistic Nursing, 2021, , 089801012110390.	0.6	3
89	Critical Period Plasticity as a Framework for Psychedelic-Assisted Psychotherapy. Frontiers in Neuroscience, 2021, 15, 710004.	1.4	32
90	Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience. European Neuropsychopharmacology, 2021, 50, 121-132.	0.3	57
91	Psychedelics, Sociality, and Human Evolution. Frontiers in Psychology, 2021, 12, 729425.	1.1	27

#	Article	IF	Citations
92	New Insights Into the Clinical and Nonclinical Effects of Psychedelic Substances. European Psychologist, $0, , \ldots$	1.8	1
93	Neuropsychological Functioning in Users of Serotonergic Psychedelics – A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 2021, 12, 739966.	1.6	4
94	Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs. International Journal of Drug Policy, 2021, 98, 103380.	1.6	21
95	Psychedelic Medicines: A Paradigm Shift from Pharmacological Substitution Towards Transformation-Based Psychiatry. , 2021, , 43-61.		5
96	Classical Psychedelics as Therapeutics in Psychiatry – Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders. Pharmacopsychiatry, 2021, 54, 176-190.	1.7	34
97	Set and Setting: A Randomized Study of Different Musical Genres in Supporting Psychedelic Therapy. ACS Pharmacology and Translational Science, 2021, 4, 472-478.	2.5	51
98	Psychedelics and Psychotherapy. Pharmacopsychiatry, 2021, 54, 167-175.	1.7	35
100	Isness: Using Multi-Person VR to Design Peak Mystical Type Experiences Comparable to Psychedelics. , 2020, , .		24
101	Hallucinogen Use in College Students: Current Trends and Consequences of Use. Current Psychopharmacology, 2020, 9, 115-127.	0.1	2
102	Psychological Antecedents to the Effects of Psychedelics on Workplace Productivity: Interview Evidence of a Naturalistic Setting. SSRN Electronic Journal, 0, , .	0.4	1
104	Buddhist Meditation and the Ethics of Human Augmentation. Journal of the Japanese Association for Digital Humanities, 2020, 5, 61-83.	0.1	1
106	Finding the divine within: exploring the role of the sacred in psychedelic integration therapy for sexual trauma and dysfunction. Sexual and Relationship Therapy, 2022, 37, 314-323.	0.7	1
107	The Role of Psychedelics and Counseling in Mental Health Treatment. Journal of Mental Health Counseling, 2020, 42, 323-338.	0.6	18
108	Novel Treatment Approaches for Substance Use Disorders: Therapeutic Use of Psychedelics and the Role of Psychotherapy. Current Addiction Reports, 2022, 9, 48-58.	1.6	7
109	Examining Psychedelic-Induced Changes in Social Functioning and Connectedness in a Naturalistic Online Sample Using the Five-Factor Model of Personality. Frontiers in Psychology, 2021, 12, 749788.	1.1	13
110	A Semantic Scale Network analysis of the revised Mystical Experiences Questionnaire: A call for collaboration. Journal of Psychedelic Studies, 2021, , .	0.5	1
111	The Potential of Psychedelics for End of Life and Palliative Care. Current Topics in Behavioral Neurosciences, 2021, , 169-184.	0.8	8
112	Psychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action. Current Topics in Behavioral Neurosciences, 2021, , 187-211.	0.8	8

#	Article	IF	CITATIONS
113	Psychedelics as Novel Therapeutics in Alzheimer's Disease: Rationale and Potential Mechanisms. Current Topics in Behavioral Neurosciences, 2021, , 287-317.	0.8	11
114	Linkages between Psychedelics and Meditation in a Population-Based Sample in the United States. Journal of Psychoactive Drugs, 2023, 55, 11-18.	1.0	10
116	Assessing the risk–benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research. Psychopharmacology, 2022, 239, 1907-1932.	1.5	36
117	Evaluating the Potential Use of Serotonergic Psychedelics in Autism Spectrum Disorder. Frontiers in Pharmacology, 2021, 12, 749068.	1.6	16
118	Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience. Journal of Psychopharmacology, 2022, 36, 31-45.	2.0	46
119	Classic Psychedelic Drugs: Update on Biological Mechanisms. Pharmacopsychiatry, 2022, 55, 121-138.	1.7	34
120	Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [11C]MDL 100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation. Frontiers in Neuroergonomics, 2022, 2,	0.6	4
121	Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective. Frontiers in Psychiatry, 2021, 12, 800072.	1.3	35
122	A potential effect of psilocybin on anxiety in neurotic personality structures in adolescents. Croatian Medical Journal, 2021, 62, 528-530.	0.2	0
124	Psychedelic Psychotherapy: Building Wholeness Through Connection. Global Advances in Health and Medicine, 2022, 11, 2164957X2210811.	0.7	8
125	Can psilocybin be safely administered under medical supervision? A systematic review of adverse event reporting in clinical trials. Drug Science, Policy and Law, 2022, 8, 205032452210852.	0.6	16
126	Human behavioral pharmacology of psychedelics. Advances in Pharmacology, 2022, 93, 105-132.	1.2	6
127	Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology, 2022, 36, 151-158.	2.0	162
128	Microdosing as a Response to the Meaning Crisis: A Qualitative Analysis. Journal of Humanistic Psychology, 0, , 002216782210750.	1.4	6
129	Virtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy. Frontiers in Psychology, 2022, 13, 813746.	1.1	9
130	How Important Is a Guide Who Has Taken Psilocybin in Psilocybin-Assisted Therapy for Depression?. Journal of Psychoactive Drugs, 2023, 55, 51-61.	1.0	16
131	Predictors and potentiators of psychedelic-occasioned mystical experiences. Journal of Psychedelic Studies, 2022, 6, 31-47.	0.5	4
134	Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report. Frontiers in Pharmacology, 2022, 13, 841648.	1.6	29

#	ARTICLE	IF	CITATIONS
135	A Single Belief-Changing Psychedelic Experience Is Associated With Increased Attribution of Consciousness to Living and Non-living Entities. Frontiers in Psychology, 2022, 13, 852248.	1.1	30
137	WILLIAM JAMES AND THE ROLE OF MYSTICISM IN RELIGION. Manuscrito, 2021, 44, 453-488.	0.1	0
138	Palliative care provider attitudes toward existential distress and treatment with psychedelic-assisted therapies. BMC Palliative Care, 2021, 20, 191.	0.8	10
139	Right-Wing Psychedelia: Case Studies in Cultural Plasticity and Political Pluripotency. Frontiers in Psychology, 2021, 12, 733185.	1.1	19
140	A Spectrum of Selves Reinforced in Multilevel Coherence: A Contextual Behavioural Response to the Challenges of Psychedelic-Assisted Therapy Development. Frontiers in Psychiatry, 2021, 12, 727572.	1.3	4
141	Psychedelic Experiences and Mindfulness are Associated with Improved Wellbeing. Journal of Psychoactive Drugs, 2023, 55, 123-133.	1.0	4
142	Strategies for Fostering a Genuine Feeling of Connection in Technologically Mediated Systems. , 2022, , .		11
143	Naturalistic use of psychedelics is related to emotional reactivity and self-consciousness: The mediating role of ego-dissolution and mystical experiences. Journal of Psychopharmacology, 2022, 36, 987-1000.	2.0	11
144	Psychedelic Mystical Experience: A New Agenda for Theology. Religions, 2022, 13, 385.	0.3	3
145	Ayahuasca Ritual, Personality and Sociality: Observational Research Conducted in a Substance Use Disorder Rehabilitation Center in Uruguay. Journal of Psychoactive Drugs, 2023, 55, 141-150.	1.0	5
146	Do psychedelics change beliefs?. Psychopharmacology, 2022, 239, 1809-1821.	1.5	7
147	The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol. Systematic Reviews, 2022, 11, 85.	2.5	2
148	Self-transcendence Predicts Better Pre- and Postoperative Outcomes in Two Randomized Clinical Trials of Brief Mindfulness-Based Interventions. Mindfulness, 2022, 13, 1532-1543.	1.6	6
150	The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences. Frontiers in Psychology, 2022, 13, .	1.1	5
151	The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955–2021) and recommendations for the field. Neuroscience and Biobehavioral Reviews, 2022, 139, 104706.	2.9	34
152	Prosocial correlates of transformative experiences at secular multi-day mass gatherings. Nature Communications, 2022, 13, .	5.8	7
153	Postpartum depression: A role for psychedelics?. Journal of Psychopharmacology, 2022, 36, 920-931.	2.0	2
154	Systematic Review of Psychometric Instruments Used in Research with Psychedelics. Journal of Psychoactive Drugs, 2023, 55, 359-368.	1.0	10

#	Article	IF	CITATIONS
155	Group VR experiences can produce ego attenuation and connectedness comparable to psychedelics. Scientific Reports, 2022, 12, .	1.6	11
156	Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model. Frontiers in Psychology, 2022, 13, .	1.1	24
157	Self-Actualization and the Integration of Psychedelic Experience: The Mediating Role of Perceived Benefits to Narrative Self-Functioning. Journal of Humanistic Psychology, 0, , 002216782210996.	1.4	1
158	Psychedelic Microdosing, Mindfulness, and Anxiety: A Cross-Sectional Mediation Study. Journal of Psychoactive Drugs, 2023, 55, 310-320.	1.0	3
159	Defining Transformative Experiences: A Conceptual Analysis. Frontiers in Psychology, 0, 13, .	1.1	15
160	Studying Close Entity Encounters of the Psychedelic Kind: Insights from the Cognitive Evolutionary Science of Religion. International Journal for the Psychology of Religion, The, 0, , 1-15.	1.3	2
161	Psychedelic therapy for body dysmorphic disorder. Journal of Psychedelic Studies, 2022, 6, 23-30.	0.5	1
162	Mystical experiences without mysticism: AnÂargument for mystical fictionalism inÂpsychedelics. Journal of Psychedelic Studies, 2022, 6, 48-53.	0.5	2
163	Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders. Frontiers in Pharmacology, $0,13,.$	1.6	2
164	Mystical Experience. Religions, 2022, 13, 589.	0.3	2
165	Psilocybin induces spatially constrained alterations in thalamic functional organizaton and connectivity. Neurolmage, 2022, 260, 119434.	2.1	9
166	Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees. Frontiers in Psychiatry, 0, 13, .	1.3	5
167	The Relationship Between Psychedelic Use, Mystical Experiences, and Pro-Environmental Behaviors. Journal of Humanistic Psychology, 0, , 002216782211110.	1.4	4
168	Reduced death anxiety and obsessive beliefs as mediators of the therapeutic effects of psychedelics on obsessive compulsive disorder symptomology. Clinical Psychologist, 0, , 1-16.	0.5	4
169	Patanjala Yoga and Buddhist Abhidharma on the Sources of Extraordinary Accomplishments (Siddhi) Tj ETQq0 0	0 rgBT /Ov	verlock 10 Tf!
170	Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review.	2.9	54
	Neuroscience and Biobehavioral Reviews, 2022, 140, 104793.	2.9	
171	Neuroscience and Biobehavioral Reviews, 2022, 140, 104793.  Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling. Neuropharmacology, 2022, 218, 109220.	2.0	16

#	Article	IF	CITATIONS
173	Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample. Journal of Psychopharmacology, 2022, 36, 932-942.	2.0	34
174	Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying. PLoS ONE, 2022, 17, e0271926.	1.1	11
175	Association between Lifetime Classic Psychedelic Use and Sick Leave in a Population-Based Sample. International Journal of Environmental Research and Public Health, 2022, 19, 11353.	1.2	7
176	Psychedelic use predicts objective knowledge about climate change via increases in nature relatedness. Drug Science, Policy and Law, 2022, 8, 205032452211298.	0.6	6
177	A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review. CNS Drugs, 2022, 36, 1031-1047.	2.7	5
178	Tripping to Cope: Coping Strategies and Use of Hallucinogens during the COVID-19 Pandemic in Three Cultural Contexts., 2022, 1, 16-30.		5
179	The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns. American Journal of Geriatric Psychiatry, 2023, 31, 44-53.	0.6	10
180	Esketamine and Psilocybin—The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review. International Journal of Molecular Sciences, 2022, 23, 11450.	1.8	6
181	Scoping Review of Experiential Measures from Psychedelic Research and Clinical Trials. Journal of Psychoactive Drugs, 2023, 55, 501-517.	1.0	7
182	Self-Transcendent Positive Emotions as a Potential Mechanism Underpinning the Effects of Meaningful Psychedelic Experiences on Connectedness to Nature. Ecopsychology, 0, , .	0.8	1
183	Neural Mechanisms and Psychology of Psychedelic Ego Dissolution. Pharmacological Reviews, 2022, 74, 876-917.	7.1	20
184	Seeing in Visionary and Mystical Experience: A Perceptual and Cognitive-Semantic Account. Cognitive Semantics, 2022, 8, 323-344.	0.4	0
185	Effects of psilocybin versus escitalopram on rumination and thought suppression in depression. BJPsych Open, 2022, 8, .	0.3	12
186	Self-Entropic Broadening Theory: Toward a New Understanding of Self and Behavior Change Informed by Psychedelics and Psychosis. Pharmacological Reviews, 2022, 74, 984-1029.	7.1	10
187	Animal Behavior in Psychedelic Research. Pharmacological Reviews, 2022, 74, 1176-1205.	7.1	5
188	Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals. Frontiers in Psychology, 0, $13$ , .	1.1	11
189	Psychosis and psychedelics: Historical entanglements and contemporary contrasts. Transcultural Psychiatry, 2022, 59, 592-609.	0.9	24
190	Psychedelic medicine at a crossroads: Advancing an integrative approach to research and practice. Transcultural Psychiatry, 2022, 59, 718-724.	0.9	3

#	Article	IF	Citations
191	Therapeutic (Sub)stance: Current practice and therapeutic conduct in preparatory sessions in substance-assisted psychotherapy—A systematized review. Journal of Psychopharmacology, 2022, 36, 1191-1207.	2.0	7
192	How Chanting Relates to Cognitive Function, Altered States and Quality of Life. Brain Sciences, 2022, 12, 1456.	1.1	2
193	Belief changes associated with psychedelic use. Journal of Psychopharmacology, 2023, 37, 80-92.	2.0	10
195	Self-transcendent experiences as promoters of ecological wellbeing? Exploration of the evidence and hypotheses to be tested. Frontiers in Psychology, 0, $13$ , .	1.1	2
196	Ethical Issues Regarding Nonsubjective Psychedelics as Standard of Care. Cambridge Quarterly of Healthcare Ethics, 2022, 31, 464-471.	0.5	10
197	Psychedelics as Standard of Care? Many Questions Remain. Cambridge Quarterly of Healthcare Ethics, 2022, 31, 477-481.	0.5	2
198	Positive Psychology and Buddhism. , 2023, , 211-225.		3
199	ĐĐ•ĐĐ•Đ¡ĐĐĐ¡ ĐŸĐ¡Đ°Đ¥ĐžĐ"Đ•Đ›Đ†Đ§ĐЎЇ Đ¢Đ•ĐĐĐŸĐ†Đ‡ Đ¢Đ•Đ‡Đ‡ Đ—ĐĐЧЕĐĐа ДЛа Đ£ĐšĐĐĐ	0‡ <b>0€</b> 2~. Lik	arsika Sprava
200	The Altered States Database: Psychometric data from a systematic literature review. Scientific Data, 2022, 9, .	2.4	7
201	Psychedelic Science of Spirituality and Religion: An Attachment-Informed Agenda Proposal. International Journal for the Psychology of Religion, The, 2023, 33, 259-276.	1.3	4
202	A unified model of ketamine's dissociative and psychedelic properties. Journal of Psychopharmacology, 2023, 37, 14-32.	2.0	8
203	Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology. Neurosurgery, 2023, 92, 680-694.	0.6	2
204	A neurophenomenological approach to non-ordinary states of consciousness: hypnosis, meditation, and psychedelics. Trends in Cognitive Sciences, 2023, 27, 139-159.	4.0	18
205	Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness. Journal of Psychopharmacology, 2023, 37, 93-106.	2.0	4
206	An Integrative Review of Measures of Spirituality in Experimental Studies of Psilocybin in Serious Illness Populations. American Journal of Hospice and Palliative Medicine, 0, , 104990912211477.	0.8	0
208	What Are the Effects of Chamber REST on the Scientific Understanding of Reality? An Exploratory Study. Journal of Consciousness Studies, 2023, 30, 163-190.	0.4	0
209	TMS-EEG and resting-state EEG applied to altered states of consciousness: oscillations, complexity, and phenomenology. IScience, 2023, 26, 106589.	1.9	8
210	Not in the drug, not in the brain: Causality in psychedelic experiences from an enactive perspective. Frontiers in Psychology, 0, 14, .	1.1	3

#	Article	IF	CITATIONS
211	The Occurrence of Psychologically Profound, Meaningful, and Mystical Experiences During a Month-Long Meditation Retreat. Mindfulness, 2023, 14, 606-621.	1.6	0
212	Reduced death anxiety as a mediator of the relationship between acute subjective effects of psychedelics and improved subjective well-being. Death Studies, 2023, 47, 1115-1126.	1.8	1
213	Ayahuasca and personality. A systematic review and meta-analysis of cross-sectional studies with long-term participants ( <i>Ayahuasca y personalidad. Revisión sistemática y metaanálisis de estudios) Tj ETQq(</i>	0 <b>0.0</b> rgBT	Dverlock 10
214	Therapeutic effect of psilocybin in addiction: A systematic review. Frontiers in Psychiatry, 0, 14, .	1.3	12
215	Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample. Scientific Reports, 2023, 13, .	1.6	1
216	Psychoanalysis and Psychedelic Psychotherapy – A New Modern Synthesis?. , 0, , .		0
217	Restructuring insight: An integrative review of insight in problem-solving, meditation, psychotherapy, delusions and psychedelics. Consciousness and Cognition, 2023, 110, 103494.	0.8	7
218	Examining the Rationale for Studying Psychedelic-Assisted Psychotherapy for the Treatment of Caregiver Distress. , 0, , .		0
219	Classic Psychedelic Use and Current Meditation Practice. Mindfulness, 2023, 14, 763-768.	1.6	5
220	Where the Spirit Meets the Bone: Embodied Religiospiritual Cognition from an Attachment Viewpoint. Religions, 2023, 14, 511.	0.3	1
221	Commentary: Evidence-Informed Recommendation to Achieve Approximate Parity in the Allowed Number of Doses for Common Psychedelics. Journal of Psychoactive Drugs, 0, , 1-5.	1.0	1
234	The Health and Clinical Benefits of Medicinal Fungi. Advances in Biochemical Engineering/Biotechnology, 2023, , .	0.6	0
241	Psychedelic-Assisted Psychotherapy and Mindfulness-Based Cognitive Therapy: Potential Synergies. Mindfulness, 2023, 14, 2111-2123.	1.6	1
251	Psychoactive drugs. , 2024, , 397-407.		0
273	Bringing It Home and Carrying It Forward. , 2024, , 252-262.		0
275	Integration Sessions. , 2024, , 204-251.		0
276	INTRODUCTION: A New Approach for the Whole Person. , 2024, , 1-9.		0
277	An Overview of Psychedelic-Assisted Therapy. , 2024, , 10-30.		0

#	Article	IF	CITATIONS
280	Medicine Sessions. , 2024, , 167-203.		0
282	Preparation Sessions., 2024, , 132-166.		O
283	Considerations Prior to Meeting With a Participant. , 2024, , 93-131.		0
284	EMBARK Mechanisms of Change in the Treatment of Depression. , 2024, , 70-92.		O
285	Introduction to the EMBARK Approach. , 2024, , 31-69.		0